AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytidine and dCMP deaminase domain-containing protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BWV3

UPID:

CDAC1_HUMAN

Alternative names:

Cytidine deaminase; Testis development protein NYD-SP15

Alternative UPACC:

Q9BWV3; Q49A08; Q4G119; Q5TAW9; Q7Z764; Q9NT36

Background:

Cytidine and dCMP deaminase domain-containing protein 1, also known as Cytidine deaminase and Testis development protein NYD-SP15, plays a crucial role in nucleotide metabolism by catalyzing the deamination of cytidine and deoxycytidine into uridine and deoxyuridine, respectively. This enzymatic activity is essential for DNA and RNA processing and repair, highlighting its significance in cellular functions. Furthermore, its involvement in testicular development and spermatogenesis suggests a specialized role in reproductive biology.

Therapeutic significance:

Understanding the role of Cytidine and dCMP deaminase domain-containing protein 1 could open doors to potential therapeutic strategies. Its pivotal function in nucleotide metabolism and testicular development positions it as a key target for interventions in reproductive health disorders and diseases related to nucleotide metabolism dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.